Please login to the form below

Not currently logged in
Email:
Password:

Novartis announces departures of three execs

Follows deals to sell divisions to GSK and Lilly

Novartis George GunnNovartis Brian McNamaraNovartis Andrin Oswald

George Gunn, Brian McNamara and Andrin Oswald

Three senior executives at Novartis are to leave the company in the wake of multibillion dollar deals the company agreed with GlaxoSmithKline (GSK) and Lilly earlier this year that effectively make their roles redundant.

George Gunn, head of Novartis animal health; Brian McNamara, head of Novartis OTC; and Andrin Oswald, head of Novartis vaccines, will all leave the Switzerland-based company once the transactions are completed in the first half of 2015.

The deals, which were agreed in April, will see Novartis acquire GSK's oncology business, with its vaccines division going in the other direction. GSK and Novartis also intend to combine their consumer health businesses, while a separate deal will see Lilly acquire Novartis' animal health division for $5.4bn.

Gunn, who joined Novartis in 2003 as head of animal health in North America, will retire once the deal with Lilly is complete. Oswald – who was also chairman of the board of the Novartis Foundation for Sustainable Development - will also leave the company completely, with Novartis stating he intends to “pursue other opportunities”.

As for McNamara – a ten-year veteran of Novartis OTC - he will move to GSK where he will become head of Americas and Europe for the combined consumer health businesses once the deal is finalised. He will report to GSK's president of consumer healthcare.

9th October 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics